Clinical features and management of intoxication due to hallucinogenic drugs
- PMID: 2682130
- DOI: 10.1007/BF03259916
Clinical features and management of intoxication due to hallucinogenic drugs
Abstract
Hallucinogenic drugs are unique in that they produce the desired hallucinogenic effects at what are considered non-toxic doses. The hallucinogenic drugs can be categorised into 4 basic groups: indole alkaloid derivatives, piperidine derivatives, phenylethylamines and the cannabinols. The drugs reviewed include lysergic acid diethylamide (LSD), phencyclidine (PCP), cocaine, amphetamines, opiates, marijuana, psilocybin, mescaline, and 'designer drugs.' Particularly noteworthy is that each hallucinogen produces characteristic behavioural effects which are related to its serotonergic, dopaminergic or adrenergic activity. Cocaine produces simple hallucinations, PCP can produce complex hallucinations analogous to a paranoid psychosis, while LSD produces a combination of hallucinations, pseudohallucinations and illusions. Dose relationships with changes in the quality of the hallucinatory experience have been described with amphetamines and, to some extent, LSD. Flashbacks have been described with LSD and alcohol. Management of the intoxicated patient is dependent on the specific behavioural manifestation elicited by the drug. The principles involve differentiating the patient's symptoms from organic (medical or toxicological) and psychiatric aetiologies and identifying the symptom complex associated with the particular drug. Panic reactions may require treatment with a benzodiazepine or haloperidol. Patients with LSD psychosis may require an antipsychotic. Patients exhibiting prolonged drug-induced psychosis may require a variety of treatments including ECT, lithium and l-5-hydroxytryptophan.
Similar articles
-
Dissociations between the effects of hallucinogenic drugs on behavior and raphe unit activity in freely moving cats.Brain Res. 1981 Jun 29;215(1-2):275-93. doi: 10.1016/0006-8993(81)90507-2. Brain Res. 1981. PMID: 6114779
-
Management of hallucinogen abuse.Am Fam Physician. 1976 Jul;14(1):82-7. Am Fam Physician. 1976. PMID: 1065215
-
Differences in the stimulus properties of 3,4-methylenedioxyamphetamine and 3,4- methylenedioxymethamphetamine in animals trained to discriminate hallucinogens from saline.J Pharmacol Exp Ther. 1988 Sep;246(3):866-70. J Pharmacol Exp Ther. 1988. PMID: 2901488
-
Hallucinogen Use Disorders.Child Adolesc Psychiatr Clin N Am. 2016 Jul;25(3):489-96. doi: 10.1016/j.chc.2016.03.006. Epub 2016 Apr 18. Child Adolesc Psychiatr Clin N Am. 2016. PMID: 27338969 Review.
-
[Hallucinogen-induced psychological disorders].Fortschr Neurol Psychiatr. 2008 Jun;76(6):334-42. doi: 10.1055/s-2008-1038191. Fortschr Neurol Psychiatr. 2008. PMID: 18512184 Review. German.
Cited by
-
Back to the Future of Neuropsychopharmacology.Adv Neurobiol. 2023;30:207-224. doi: 10.1007/978-3-031-21054-9_9. Adv Neurobiol. 2023. PMID: 36928852
-
Chemistry and Toxicology of Major Bioactive Substances in Inocybe Mushrooms.Int J Mol Sci. 2021 Feb 23;22(4):2218. doi: 10.3390/ijms22042218. Int J Mol Sci. 2021. PMID: 33672330 Free PMC article. Review.
-
Cytotoxic, genotoxic, and oxidative stress-related effects of lysergic acid diethylamide (LSD) and phencyclidine (PCP) in the human neuroblastoma SH-SY5Y cell line.Arh Hig Rada Toksikol. 2021 Dec 30;72(4):333-342. doi: 10.2478/aiht-2021-72-3604. Arh Hig Rada Toksikol. 2021. PMID: 34985843 Free PMC article.
-
Recreational drug misuse: issues for the cardiologist.Heart. 2000 Jun;83(6):627-33. doi: 10.1136/heart.83.6.627. Heart. 2000. PMID: 10814617 Free PMC article. Review. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources